Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;77(5):547-561.
doi: 10.1007/s40265-017-0712-6.

The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus

Affiliations
Review

The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus

David A Johnson et al. Drugs. 2017 Apr.

Abstract

The availability of over-the-counter (OTC) proton pump inhibitors (PPIs) for the short-term (2 weeks) management of frequent heartburn (≥2 days/week) has increased markedly, yet evidence-based recommendations have not been developed. A panel of nine international experts in gastroesophageal reflux disease developed consensus statements regarding the risks and benefits of OTC PPIs using a modified Delphi process. Consensus (based on ≥80% approval) was reached through multiple rounds of remote voting and a final round of live voting. To identify relevant data, the available literature was searched and summarized. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system terminology was used to rate the quality of evidence and strength of recommendations; consensus was based on ≥2/3 agreement. After 4 rounds of review, consensus was achieved for 18 statements. Notably, the available data did not directly reflect OTC use, but instead, prescription use; therefore, extrapolations to the OTC setting were often necessary. This limitation is regrettable, but it justifies performing this exercise to provide evidence-based expert opinion on a widely used class of drugs. The panel determined that using OTC PPIs according to label instructions is unlikely to mask the symptoms of esophageal or gastric cancer or adversely impact the natural history of related precursor conditions. OTC PPIs are not expected to substantially affect micronutrient absorption or bone mineral density or cause community-acquired pneumonia, Clostridium difficile infection, or cardiovascular adverse events. However, OTC PPI use may be associated with slightly increased risks for infectious diarrhea, certain idiosyncratic reactions, and cirrhosis-related spontaneous bacterial peritonitis. The available evidence does not suggest that OTC PPI use consistent with label instructions is associated with substantial health risks. To minimize potential risks, healthcare professionals and consumers must actively participate in decision making when managing reflux-related symptoms in the self-care setting.

PubMed Disclaimer

Conflict of interest statement

Financial support

Pfizer Consumer Healthcare provided funding for the live consensus panel meeting and provided recommendations and background information on prospective members of the panel (with final decisions determined by the co-chairs). Literature search assistance and writing/editorial assistance for the publication were provided by Dennis Stancavish, MA, and Diane Sloan, PharmD, of Peloton Advantage and were funded by Pfizer.

Potential conflict of interest

David A. Johnson, MD, is a paid consultant to Pfizer Consumer Healthcare and serves as an advisor for Pfizer. Philip O. Katz, MD, is a paid consultant to Pfizer Consumer Healthcare. David Armstrong, MA, MB BChir, has received an honorarium from Pfizer Consumer Healthcare and serves as an advisor for Pfizer. Henry Cohen, MD, has received an honorarium from Pfizer Consumer Healthcare. Brendan C. Delaney, MD, is a paid consultant to Pfizer Consumer Healthcare. Colin W. Howden, MD, has received an honorarium from Pfizer Consumer Healthcare. Peter Katelaris, MD, is a paid consultant to Pfizer Consumer Healthcare. Radu I. Tutuian, MD, PhD, has received an honorarium from Pfizer Consumer Healthcare. Donald O. Castell, MD, has no conflicts to disclose.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Similar articles

Cited by

References

    1. Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin. 2015;31(7):1309–1318. doi: 10.1185/03007995.2015.1047745. - DOI - PubMed
    1. Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi: 10.1186/s12916-016-0718-z. - DOI - PMC - PubMed
    1. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896–903. doi: 10.1016/j.amjmed.2009.04.014. - DOI - PubMed
    1. Prilosec [package insert]. Wilmington: AstraZeneca Pharmaceuticals; 2012.
    1. Prilosec OTC [product monograph]. Cincinnati: Procter & Gamble; 2014.

MeSH terms

Substances